Avecho Biotechnology Ltd
ASX:AVE
Avecho Biotechnology Ltd
Research & Development
Avecho Biotechnology Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Avecho Biotechnology Ltd
ASX:AVE
|
Research & Development
-AU$3.7m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-99%
|
CAGR 10-Years
-3%
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Research & Development
-AU$17.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Research & Development
-AU$30m
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-9%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Research & Development
-AU$66.9m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Research & Development
-AU$4.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
Avecho Biotechnology Ltd
Glance View
Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.
See Also
What is Avecho Biotechnology Ltd's Research & Development?
Research & Development
-3.7m
AUD
Based on the financial report for Jun 30, 2025, Avecho Biotechnology Ltd's Research & Development amounts to -3.7m AUD.
What is Avecho Biotechnology Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-3%
Over the last year, the Research & Development growth was -27%. The average annual Research & Development growth rates for Avecho Biotechnology Ltd have been -22% over the past three years , -99% over the past five years , and -3% over the past ten years .